Sep 11, 2018 - Background & Objective: Primary central nervous system lymphoma. (PCNSL) is an extra nodal non-Hodgkin lymphoma conned to the brain,.
S144
PS-16-017 Primary central nervous system lymphoma: clinico-pathological correlation M. Atienza*, P. Lopez Sala, L. Nova Camacho, A. Panizo, M. Victoria Zelaya * Hospital Universitario Cruces, Anatomía Patológica, Pamplona/Iruña, Spain Background & Objective: Primary central nervous system lymphoma (PCNSL) is an extra nodal non-Hodgkin lymphoma conned to the brain, leptomeninges, spinal cord, or eyes, without systemic involvement. The typical radiological findings consist of a brain tumour that enhances homogeneously, multifocal and with incomplete ring enhancement. The differential diagnosis of PCNSL should consider other malignant tumours of the CNS such as glioblastomas or metastases. The goal of our study is to describe the histopathological characteristics and clinic-radiological correlation. Method: Retrospective review of all the patients diagnosed of primary CNS tumours in our center in the last 10 years (2008-2018). We described PCNSL and collected clinical and radiological information such as age, sex, location and histological types. Survival and immunosuppression as well. Results: We identified 15 patients, 4 women and 11 men with a mean age of 66 years old. 73,3% were located in the brain hemispheres, 13,3 % in the corpus callosum, 6,6 in the cerebellum and 6,6% in the brain stem. The last location present the shorter survival as well. Clinical pathology correlation was high, up to 80% of cases considered lymphoma within the differential diagnosis. The most frequent histological type was diffuse large B cell lymphoma (80%) and 13,3% patients were associated with immunosuppression. Conclusion: Despite its low frequency LPSNC should be considered as a differential diagnosis within brain tumours. In our review the most frequent subtype of CNS lymphomas correspond to diffuse large B-cell lymphoma as it is described in the literature. Despite the high correlation with radiology, histological confirmation is still necessary.
PS-16-018 Prognostic value of immunohistochemical expression of EGFR in glioblastomas I. Msakni*, H. Kammoun, N. Redissi, N. Mansouri, F. Gargouri, R. Yaiche, A. Bouziani, B. Laabidi * Military Hospital of Tunis, Dept. of Pathology, Tunisia Background & Objective: Glioblastomas are the most prevalent primary brain malignancy and the prognosis is poor. Age, cognitive status, extent of surgical resection and adjuvant treatment are among the main prognostic factors. Some immunohistochemical markers seem to have a prognostic interest but the results are not unanimous and are sometimes contradictory. The aim of our study was to evaluate the prognostic value of EGFR antibody in glioblastomas and to find a statistically significant relationship between the expression of this antibody and the recurrence. Method: Fifty-two cases of glioblastoma were identified in the Department of pathology of the Military Hospital of Tunis between 2005 and 2016. An immunohistochemical study was performed followed by a statistical analysis analysing the correlation with the recurrence and the overall survival. Results: The average age of patients was 56 years old. The 1-year survival and 2-year survival were 33% and 4% respectively. The median progression-free survival was 26 weeks. The median survival was 35 weeks. There was Tumour recurrence in 37% of cases. EGFR was expressed in 87% of cases and had a percentage of marked cells of 100% in quarter of cases. EGFR labeling was intense in 38% of cases. EGFR had a statistically significant positive relationship with progression-free survival but it has no statistically significant relationship with overall survival.
Virchows Archiv (2018) 473 (Suppl 1):S1–S340
Conclusion: Our study concluded that EGFR could have a role in prolonging progression-free survival. As the immunohistochemical expression of EGFR is inversely correlated with recurrence, it could intervene in the rhythm and frequency of postoperative controls in order to optimize the therapeutic management in time.
PS-16-019 Pleomorphic pineocytoma, a mimicker of a high grade lesion L. Zaldumbide*, I. Vicente Olabarria, G. Catalán Uribarrena, P. Cabrerizo Muñoz, E. Fernandez-Lomana, M. Atienza Robles, A. Nogueira Gregorio, A. Marcos Muñoz, G. García de Casasola, I. Diaz de Lezcano, D. Parrón Collar * Cruces University Hospital, Pathology, Barakaldo, Spain Background & Objective: Pineal parenchymal tumours (PPTs) account for
